Updating the diagnosis and management of elevated serum ferritin levels in the era of routine ferritin testing of blood donors by Australian Red Cross Lifeblood

IF 8.5 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Medical Journal of Australia Pub Date : 2025-02-27 DOI:10.5694/mja2.52618
Gary D Zhang, James Chen, Daniel M Johnstone, Martin B Delatycki, Katie Allen, John K Olynyk
{"title":"Updating the diagnosis and management of elevated serum ferritin levels in the era of routine ferritin testing of blood donors by Australian Red Cross Lifeblood","authors":"Gary D Zhang,&nbsp;James Chen,&nbsp;Daniel M Johnstone,&nbsp;Martin B Delatycki,&nbsp;Katie Allen,&nbsp;John K Olynyk","doi":"10.5694/mja2.52618","DOIUrl":null,"url":null,"abstract":"<p>Elevated serum ferritin levels (hyperferritinaemia) can reflect a wide range of conditions and are not solely indicative of iron overload. A thorough clinical assessment is required to identify serious causes of high serum ferritin levels, evaluate iron status and manage associated complications.</p><p>The upper limit of the reference interval for serum ferritin values varies between laboratories due to different testing methods, and the Royal College of Pathologists of Australasia no longer specifies upper limits in its guidance to laboratories.<span><sup>1</sup></span> Up to 20% of men have elevated serum ferritin concentrations, while the prevalence in women varies from 3% in premenopausal women to 17% in women older than 70 years.<span><sup>2</sup></span> Less than 10% of cases of hyperferritinaemia are due to iron overload.<span><sup>3-5</sup></span></p><p>In August 2023, the Australian Red Cross Lifeblood introduced routine ferritin testing for its new blood donors (over 100 000 people per year),<span><sup>6</sup></span> with plans to expand testing to all whole blood donors. Donors are formally advised if their results are outside the sex-based reference intervals of 15–400 μg/L for female donors and 30–500 μg/L for male donors.<span><sup>7</sup></span> Based on Australian adult population data, about 10% of men and 2% of women will exceed these upper limit thresholds of serum ferritin levels.<span><sup>8</sup></span> This will likely result in a considerable increase in adults with elevated serum ferritin levels being identified and referred to their primary care physician for evaluation. This medical education article provides a guide for the investigation and management of elevated serum ferritin levels.</p><p>Serum ferritin levels may be elevated due to either an iron overload disorder or a non-iron overload disorder, with these aetiologies described in Box 1. The key principle guiding assessment of elevated serum ferritin values in adults is to differentiate between iron overload and non-iron overload causes, as this guides decision making related to treatment. Non-iron overload hyperferritinaemia occurs from the acute phase reactant properties of ferritin, and is commonly observed in inflammation, obesity, infections, malignancy and hepatocellular injury.<span><sup>5</sup></span></p><p>The approach to investigating an elevated serum ferritin result is described in Box 2. Individuals may have existing diagnoses that increase serum ferritin levels, such as inflammatory conditions, chronic liver disease, malignancy, excessive iron supplementation, or recurrent blood transfusions.<span><sup>5</sup></span> The initial clinical assessment should consider the following more common non-iron overload causes: acute illness, infections (full blood count and C-reactive protein tests), alcohol intake, risk factors for liver disease (liver function tests and abdominal ultrasonography), metabolic syndrome or dysfunction (lipid studies and fasting serum glucose or glycated haemoglobin test<span><sup>9</sup></span>), family history (iron overload and other associated conditions), as red flags for malignancy, chronic inflammatory conditions and renal impairment.<span><sup>5, 10, 11</sup></span></p><p>A follow-up measurement of the serum ferritin level should be repeated at least six weeks after an elevated result to allow for sufficient time for acute illness to resolve, along with measurement of the serum transferrin saturation level in the morning and while fasted to reduce the variabilities in serum iron levels due to diet and diurnal fluctuations.<span><sup>12</sup></span> A serum transferrin saturation value of 45% or greater is consistent with, but not diagnostic of, iron overload, and predicts <i>HFE</i>-related haemochromatosis with high sensitivity in people with European ancestry, with care taken in determining this aspect in multicultural societies such as Australia.<span><sup>13</sup></span> Iron overload is unlikely if the transferrin saturation value is less than 45%.<span><sup>3, 13, 14</sup></span></p><p>As shown in Box 2, if the repeat testing demonstrates both the serum ferritin level and transferrin saturation within the reference interval, no further action is required, as treatable iron overload disorders are highly unlikely.<span><sup>11, 13, 14</sup></span> If the serum ferritin level and transferrin saturation are both elevated, further assessment should be undertaken for the presence of <i>HFE</i>-related haemochromatosis, due to p.Cys282Tyr homozygosity, in individuals with European ancestry or if there is uncertainty regarding European ancestry. Likewise, testing for the <i>HFE</i> p.Cys282Tyr mutation is strongly suggested when there is a family history of haemochromatosis or iron overload,<span><sup>4, 13</sup></span> as p.Cys282Tyr homozygosity accounts for almost all <i>HFE</i> haemochromatosis in Australia, with the remaining genotypic variations of little or no clinical significance.<span><sup>13-16</sup></span> Further diagnosis and management strategies for haemochromatosis are covered elsewhere.<span><sup>13, 14</sup></span> If <i>HFE</i> haemochromatosis is excluded, further assessment for the presence of porphyria cutanea tarda (PCT) or other haematological causes of iron overload is indicated. Where there is doubt as to the presence or absence of iron overload, quantification of liver iron concentration (LIC) using an available magnetic resonance imaging (MRI) method is indicated.<span><sup>17, 18</sup></span></p><p>Specialist haematology or hepatology referral for patients with a serum ferritin value greater than 1000 μg/L but no identified iron overload disorder should only be considered when elevation of the LIC above the reference interval has been confirmed with an available MRI-based method.<span><sup>13</sup></span> A LIC within the reference interval excludes iron overload as a cause of hyperferritinaemia and precludes the need for iron-focused management of the elevated serum ferritin level.</p><p>Treatment targeting iron overload as the cause of elevated ferritin levels is only clinically indicated for <i>HFE</i>-related haemochromatosis, PCT, or secondary iron overload associated with exogenous iron administration or haematological disorders, such as thalassaemia and other haemoglobinopathies. Therapeutic phlebotomy is the treatment of choice only for hyperferritinaemia caused by <i>HFE</i>-related haemochromatosis or PCT. There is no indication for any iron reduction treatment when a non-iron overload disorder has been diagnosed as the cause of hyperferritinaemia.<span><sup>13</sup></span> Further management and complications of <i>HFE</i> haemochromatosis and other iron overload disorders are discussed in detail elsewhere.<span><sup>10, 13, 14, 19</sup></span></p><p>Serum ferritin levels above the reference interval must always be assessed further. Iron overload accounts for less than 10% of individuals with hyperferritinaemia, and when present is usually associated with an elevated serum transferrin saturation above 45%. In individuals with European ancestry, <i>HFE</i> genotyping must be performed when persistent elevation of serum ferritin levels and transferrin saturation are confirmed, or when there is a family history of the disorder. Hyperferritinaemia without iron overload can result from a wide range of potentially serious causes, which should be evaluated initially with routine investigations, but these do not require specific treatment to reduce body iron or serum ferritin levels as there is no evidence for any benefit to be derived from such interventions.</p><p>No relevant disclosures.</p><p>Not commissioned; externally peer reviewed.</p>","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"222 7","pages":"334-336"},"PeriodicalIF":8.5000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52618","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Journal of Australia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.5694/mja2.52618","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Elevated serum ferritin levels (hyperferritinaemia) can reflect a wide range of conditions and are not solely indicative of iron overload. A thorough clinical assessment is required to identify serious causes of high serum ferritin levels, evaluate iron status and manage associated complications.

The upper limit of the reference interval for serum ferritin values varies between laboratories due to different testing methods, and the Royal College of Pathologists of Australasia no longer specifies upper limits in its guidance to laboratories.1 Up to 20% of men have elevated serum ferritin concentrations, while the prevalence in women varies from 3% in premenopausal women to 17% in women older than 70 years.2 Less than 10% of cases of hyperferritinaemia are due to iron overload.3-5

In August 2023, the Australian Red Cross Lifeblood introduced routine ferritin testing for its new blood donors (over 100 000 people per year),6 with plans to expand testing to all whole blood donors. Donors are formally advised if their results are outside the sex-based reference intervals of 15–400 μg/L for female donors and 30–500 μg/L for male donors.7 Based on Australian adult population data, about 10% of men and 2% of women will exceed these upper limit thresholds of serum ferritin levels.8 This will likely result in a considerable increase in adults with elevated serum ferritin levels being identified and referred to their primary care physician for evaluation. This medical education article provides a guide for the investigation and management of elevated serum ferritin levels.

Serum ferritin levels may be elevated due to either an iron overload disorder or a non-iron overload disorder, with these aetiologies described in Box 1. The key principle guiding assessment of elevated serum ferritin values in adults is to differentiate between iron overload and non-iron overload causes, as this guides decision making related to treatment. Non-iron overload hyperferritinaemia occurs from the acute phase reactant properties of ferritin, and is commonly observed in inflammation, obesity, infections, malignancy and hepatocellular injury.5

The approach to investigating an elevated serum ferritin result is described in Box 2. Individuals may have existing diagnoses that increase serum ferritin levels, such as inflammatory conditions, chronic liver disease, malignancy, excessive iron supplementation, or recurrent blood transfusions.5 The initial clinical assessment should consider the following more common non-iron overload causes: acute illness, infections (full blood count and C-reactive protein tests), alcohol intake, risk factors for liver disease (liver function tests and abdominal ultrasonography), metabolic syndrome or dysfunction (lipid studies and fasting serum glucose or glycated haemoglobin test9), family history (iron overload and other associated conditions), as red flags for malignancy, chronic inflammatory conditions and renal impairment.5, 10, 11

A follow-up measurement of the serum ferritin level should be repeated at least six weeks after an elevated result to allow for sufficient time for acute illness to resolve, along with measurement of the serum transferrin saturation level in the morning and while fasted to reduce the variabilities in serum iron levels due to diet and diurnal fluctuations.12 A serum transferrin saturation value of 45% or greater is consistent with, but not diagnostic of, iron overload, and predicts HFE-related haemochromatosis with high sensitivity in people with European ancestry, with care taken in determining this aspect in multicultural societies such as Australia.13 Iron overload is unlikely if the transferrin saturation value is less than 45%.3, 13, 14

As shown in Box 2, if the repeat testing demonstrates both the serum ferritin level and transferrin saturation within the reference interval, no further action is required, as treatable iron overload disorders are highly unlikely.11, 13, 14 If the serum ferritin level and transferrin saturation are both elevated, further assessment should be undertaken for the presence of HFE-related haemochromatosis, due to p.Cys282Tyr homozygosity, in individuals with European ancestry or if there is uncertainty regarding European ancestry. Likewise, testing for the HFE p.Cys282Tyr mutation is strongly suggested when there is a family history of haemochromatosis or iron overload,4, 13 as p.Cys282Tyr homozygosity accounts for almost all HFE haemochromatosis in Australia, with the remaining genotypic variations of little or no clinical significance.13-16 Further diagnosis and management strategies for haemochromatosis are covered elsewhere.13, 14 If HFE haemochromatosis is excluded, further assessment for the presence of porphyria cutanea tarda (PCT) or other haematological causes of iron overload is indicated. Where there is doubt as to the presence or absence of iron overload, quantification of liver iron concentration (LIC) using an available magnetic resonance imaging (MRI) method is indicated.17, 18

Specialist haematology or hepatology referral for patients with a serum ferritin value greater than 1000 μg/L but no identified iron overload disorder should only be considered when elevation of the LIC above the reference interval has been confirmed with an available MRI-based method.13 A LIC within the reference interval excludes iron overload as a cause of hyperferritinaemia and precludes the need for iron-focused management of the elevated serum ferritin level.

Treatment targeting iron overload as the cause of elevated ferritin levels is only clinically indicated for HFE-related haemochromatosis, PCT, or secondary iron overload associated with exogenous iron administration or haematological disorders, such as thalassaemia and other haemoglobinopathies. Therapeutic phlebotomy is the treatment of choice only for hyperferritinaemia caused by HFE-related haemochromatosis or PCT. There is no indication for any iron reduction treatment when a non-iron overload disorder has been diagnosed as the cause of hyperferritinaemia.13 Further management and complications of HFE haemochromatosis and other iron overload disorders are discussed in detail elsewhere.10, 13, 14, 19

Serum ferritin levels above the reference interval must always be assessed further. Iron overload accounts for less than 10% of individuals with hyperferritinaemia, and when present is usually associated with an elevated serum transferrin saturation above 45%. In individuals with European ancestry, HFE genotyping must be performed when persistent elevation of serum ferritin levels and transferrin saturation are confirmed, or when there is a family history of the disorder. Hyperferritinaemia without iron overload can result from a wide range of potentially serious causes, which should be evaluated initially with routine investigations, but these do not require specific treatment to reduce body iron or serum ferritin levels as there is no evidence for any benefit to be derived from such interventions.

No relevant disclosures.

Not commissioned; externally peer reviewed.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
澳大利亚红十字会生命血液对献血者进行常规铁蛋白检测时代血清铁蛋白水平升高的最新诊断和管理。
血清铁蛋白水平升高(高铁蛋白血症)可以反映多种情况,而不仅仅是铁超载的指示。需要进行彻底的临床评估,以确定高血清铁蛋白水平的严重原因,评估铁状态并管理相关并发症。血清铁蛋白值参考区间的上限因检测方法不同而在各实验室有所不同,澳大利亚皇家病理学家学院在其实验室指南中不再规定上限高达20%的男性血清铁蛋白浓度升高,而女性的患病率从绝经前妇女的3%到70岁以上妇女的17%不等不到10%的高铁血症病例是由铁超载引起的。2023年8月,澳大利亚红十字会Lifeblood对其新献血者(每年超过10万人)引入了常规铁蛋白检测,6并计划将检测范围扩大到所有全血献血者。如果献血者的结果超出基于性别的参考区间(女性献血者15-400 μg/L,男性献血者30-500 μg/L),将正式通知献血者根据澳大利亚成年人口数据,大约10%的男性和2%的女性将超过血清铁蛋白水平的上限阈值这可能会导致血清铁蛋白水平升高的成年人数量大幅增加,并将其转介给初级保健医生进行评估。这篇医学教育文章为血清铁蛋白水平升高的调查和处理提供指导。血清铁蛋白水平升高可能是由于铁超载紊乱或非铁超载紊乱,这些病因见框1。评估成人血清铁蛋白升高的关键原则是区分铁超载和非铁超载原因,因为这可以指导与治疗相关的决策。非铁超载高铁蛋白血症是由铁蛋白的急性期反应物特性引起的,常见于炎症、肥胖、感染、恶性肿瘤和肝细胞损伤。研究血清铁蛋白升高结果的方法见方框2。个体可能已有血清铁蛋白水平升高的诊断,如炎症、慢性肝病、恶性肿瘤、过量补铁或反复输血初步临床评估应考虑以下更常见的非铁超载原因:急性疾病、感染(全血细胞计数和c反应蛋白测试)、酒精摄入、肝脏疾病的危险因素(肝功能测试和腹部超声检查)、代谢综合征或功能障碍(脂质研究和空腹血糖或糖化血红蛋白测试9)、家族史(铁超载和其他相关疾病),这些都是恶性肿瘤、慢性炎症和肾脏损害的危险信号。5,10,11血清铁蛋白水平的随访测量应在升高结果至少六周后重复进行,以便有足够的时间让急性疾病消退,同时在早晨和禁食时测量血清转铁蛋白饱和水平,以减少因饮食和昼夜波动引起的血清铁水平的变化血清转铁蛋白饱和值为45%或更高,与铁超载一致,但不能诊断铁超载,并且在欧洲血统人群中预测高敏感性的hfe相关血色素病,在澳大利亚等多元文化社会中确定这方面时要小心。13如果转铁蛋白饱和值小于45%,铁超载是不可能的。3、13、14如框2所示,如果重复检测显示血清铁蛋白水平和转铁蛋白饱和度在参考区间内,则无需进一步治疗,因为可治疗的铁超载疾病极不可能发生。11,13,14如果血清铁蛋白水平和转铁蛋白饱和度均升高,则应对欧洲血统或欧洲血统不确定的个体进行进一步评估,以确定是否存在与hfe相关的血色素沉着病,原因是p.Cys282Tyr纯合性。同样,当有血色素沉着病或铁超载家族史时,强烈建议检测HFE p.Cys282Tyr突变4,13,因为p.Cys282Tyr纯合性几乎占澳大利亚所有HFE血色素沉着病的原因,其余的基因型变异很少或没有临床意义。13-16血色病的进一步诊断和管理策略在其他地方有介绍。13,14如果排除HFE血色素沉着症,则需要进一步评估是否存在迟发性皮肤卟啉症(PCT)或其他铁超载的血液学原因。 当存在或不存在铁过载的疑问时,建议使用可用的磁共振成像(MRI)方法定量肝铁浓度(LIC)。17,18对于血清铁蛋白值大于1000 μg/L但未发现铁超载障碍的患者,只有在使用可用的基于mri的方法确认LIC升高高于参考区间时,才应考虑转诊血液学或肝病学专家13在参考区间内的LIC排除了铁超载作为高铁蛋白血症的原因,并排除了对血清铁蛋白水平升高进行铁聚焦管理的需要。将铁超载作为铁蛋白水平升高原因的治疗仅适用于hfe相关的血色素沉着病、PCT或与外源性铁给药或血液学疾病(如地中海贫血和其他血红蛋白病)相关的继发性铁超载。治疗性静脉切开术仅适用于由高铁相关性血色素沉着病或PCT引起的高铁血症,当诊断为高铁血症的病因为非铁超载疾病时,没有任何铁还原治疗的适应症HFE血色素沉着病和其他铁超载疾病的进一步处理和并发症在其他地方详细讨论。10,13,14,19高于参考区间的血清铁蛋白水平必须进一步评估。铁超载占高铁血症患者的不到10%,当铁超载出现时,通常与血清转铁蛋白饱和度升高45%以上有关。在具有欧洲血统的个体中,当确认血清铁蛋白水平和转铁蛋白饱和度持续升高或有该病家族史时,必须进行HFE基因分型。无铁超载的高铁血症可由多种潜在的严重原因引起,应通过常规调查初步评估,但这些不需要特殊治疗来降低体内铁或血清铁蛋白水平,因为没有证据表明此类干预措施可带来任何益处。无相关披露。不是委托;外部同行评审。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Medical Journal of Australia
Medical Journal of Australia 医学-医学:内科
CiteScore
9.40
自引率
5.30%
发文量
410
审稿时长
3-8 weeks
期刊介绍: The Medical Journal of Australia (MJA) stands as Australia's foremost general medical journal, leading the dissemination of high-quality research and commentary to shape health policy and influence medical practices within the country. Under the leadership of Professor Virginia Barbour, the expert editorial team at MJA is dedicated to providing authors with a constructive and collaborative peer-review and publication process. Established in 1914, the MJA has evolved into a modern journal that upholds its founding values, maintaining a commitment to supporting the medical profession by delivering high-quality and pertinent information essential to medical practice.
期刊最新文献
Advancing Inclusive Design Practice for Queer Youth Using Digital Technologies for Mental Health Awareness, Usage and Perceptions of Doxycycline Post-Exposure Prophylaxis (doxyPEP) for Prevention of Sexually Transmitted Infections in Australia: Insights From a National Cross-Sectional Survey Community Code Blue: The Sydney Jewish Community's Medical Preparations and Response to the Bondi Beach Terror Attack of December 2025 Genomic Newborn Screening: Verdict From an Australian Citizens’ Jury Deprescribing in Older People: A Clinical Practice Guideline Summary
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1